BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18374895)

  • 21. Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
    Chevolet I; Speeckaert R; Haspeslagh M; Neyns B; Krüse V; Schreuer M; Van Gele M; Van Geel N; Brochez L
    Br J Dermatol; 2014 Nov; 171(5):987-95. PubMed ID: 24814041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI).
    Testori A; De Salvo GL; Montesco MC; Trifirò G; Mocellin S; Landi G; Macripò G; Carcoforo P; Ricotti G; Giudice G; Picciotto F; Donner D; Di Filippo F; Soteldo J; Casara D; Schiavon M; Vecchiato A; Pasquali S; Baldini F; Mazzarol G; Rossi CR;
    Ann Surg Oncol; 2009 Jul; 16(7):2018-27. PubMed ID: 19132446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune cell profile of sentinel lymph nodes in patients with malignant melanoma - FOXP3+ cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome.
    Mohos A; Sebestyén T; Liszkay G; Plótár V; Horváth S; Gaudi I; Ladányi A
    J Transl Med; 2013 Feb; 11():43. PubMed ID: 23418928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape.
    Simonetti O; Goteri G; Lucarini G; Filosa A; Pieramici T; Rubini C; Biagini G; Offidani A
    Eur J Cancer; 2006 May; 42(8):1181-7. PubMed ID: 16644201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regional recurrence after negative sentinel lymph node biopsy for melanoma.
    Carlson GW; Page AJ; Cohen C; Parker D; Yaar R; Li A; Hestley A; Delman KA; Murray DR
    Ann Surg; 2008 Sep; 248(3):378-86. PubMed ID: 18791358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes.
    van Akkooi AC; Nowecki ZI; Voit C; Schäfer-Hesterberg G; Michej W; de Wilt JH; Rutkowski P; Verhoef C; Eggermont AM
    Ann Surg; 2008 Dec; 248(6):949-55. PubMed ID: 19092339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma.
    Torisu-Itakura H; Lee JH; Scheri RP; Huynh Y; Ye X; Essner R; Morton DL
    Clin Cancer Res; 2007 Jun; 13(11):3125-32. PubMed ID: 17545514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers.
    Vetto JT; Lum S; Morris A; Sicotte M; Davis J; Lemon M; Weinberg A
    Am J Surg; 1997 Sep; 174(3):258-65. PubMed ID: 9324133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sentinel lymphadenectomy for cutaneous melanoma: who, what, and why.
    Bower M; Scoggins CR
    J Ky Med Assoc; 2009 Jul; 107(7):253-8. PubMed ID: 19678500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma.
    Elliott B; Scolyer RA; Suciu S; Lebecque S; Rimoldi D; Gugerli O; Musat E; Sharma RN; Lienard D; Keilholz U; Testori A; Eggermont A; MacKie R; Robert C; Cook M; Thompson JF; Angevin E; Spatz A;
    Clin Cancer Res; 2007 Jul; 13(13):3825-30. PubMed ID: 17606713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment expression of the adhesion molecules, CD134 and CD137, in patients with colorectal cancer by flow cytometry.
    Cepowicz D; Stasiak-Barmuta A; Zalewski B; Piotrowski Z
    Rocz Akad Med Bialymst; 2004; 49 Suppl 1():34-6. PubMed ID: 15638367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma?
    Frankel TL; Griffith KA; Lowe L; Wong SL; Bichakjian CK; Chang AE; Cimmino VM; Bradford CR; Rees RS; Johnson TM; Sabel MS
    Ann Surg Oncol; 2008 Sep; 15(9):2403-11. PubMed ID: 18626721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sentinel node biopsy in patients with cutaneous melanoma of the head and neck: recurrence and survival study.
    Gomez-Rivera F; Santillan A; McMurphey AB; Paraskevopoulos G; Roberts DB; Prieto VG; Myers JN
    Head Neck; 2008 Oct; 30(10):1284-94. PubMed ID: 18704971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.
    Verdijk P; Aarntzen EH; Lesterhuis WJ; Boullart AC; Kok E; van Rossum MM; Strijk S; Eijckeler F; Bonenkamp JJ; Jacobs JF; Blokx W; Vankrieken JH; Joosten I; Boerman OC; Oyen WJ; Adema G; Punt CJ; Figdor CG; de Vries IJ
    Clin Cancer Res; 2009 Apr; 15(7):2531-40. PubMed ID: 19318472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis.
    Xiaoyan Z; Pirskanen R; Malmstrom V; Lefvert AK
    Clin Exp Immunol; 2006 Jan; 143(1):110-6. PubMed ID: 16367941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
    Molenkamp BG; Sluijter BJ; van Leeuwen PA; Santegoets SJ; Meijer S; Wijnands PG; Haanen JB; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Clin Cancer Res; 2008 Jul; 14(14):4532-42. PubMed ID: 18628468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors of cutaneous melanoma in relation to metastasis at the sentinel lymph node: a case-controlled study.
    Sartore L; Papanikolaou GE; Biancari F; Mazzoleni F
    Int J Surg; 2008 Jun; 6(3):205-9. PubMed ID: 18417434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes.
    Gerlini G; Urso C; Mariotti G; Di Gennaro P; Palli D; Brandani P; Salvadori A; Pimpinelli N; Reali UM; Borgognoni L
    Clin Immunol; 2007 Nov; 125(2):184-93. PubMed ID: 17827069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients.
    Baruah P; Lee M; Odutoye T; Williamson P; Hyde N; Kaski JC; Dumitriu IE
    Immunobiology; 2012 Jul; 217(7):669-75. PubMed ID: 22204816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.